Inhaled therapeutics are used routinely to treat a variety of pulmonary diseases including asthma, COPD and
cystic fibrosis. In addition, biological therapies represent the fastest growing segment of approved pharmaceuticals.
However, despite the increased availability of biological therapies, nearly all inhaled therapeutics are small molecule
drugs with only a single inhaled protein therapeutic approved. There remains a significant unmet need for therapeutics in
pulmonary diseases, and biological therapies with potential to alter disease progression represent a significant opportunity
to treat these challenging diseases. This review provides a background into efforts to develop inhaled biological therapies
and highlights some of the associated challenges. In addition, we speculate on the ideal properties of a biologic therapy for
Keywords: Alternative scaffolds, inhalation, protein therapeutics, pulmonary delivery.
Rights & PermissionsPrintExport